Analyst ratings and price targets can significantly influence a stock's performance. In this case, the 'Buy' rating maintained by HC Wainwright & Co. and the raised price target from $28 to $33 indicate a positive outlook for ACADIA Pharmaceuticals, which could potentially lead to an increase in its stock price in the short term.